Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT02231164	Phase III	Docetaxel Nintedanib	LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research	Terminated	USA	2
NCT02898116	Phase Ib/II	Durvalumab + Ensartinib Ensartinib	A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer	Completed	USA	0
NCT01871805	Phase Ib/II	Alectinib	A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer	Completed	USA \| CAN	0
NCT02013219	Phase I	Alectinib + Atezolizumab Atezolizumab + Erlotinib	A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer	Completed	USA \| GBR \| FRA \| ESP	2
NCT01948141	Phase II	Nintedanib	Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens	Completed	USA	0
NCT03840915	Phase Ib/II	Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel	M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| FRA \| BEL	0
NCT05568212	Phase II	Durvalumab Durvalumab + Olaparib	Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab	Recruiting	ITA	0
NCT02414139	Phase II	Capmatinib	Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1)	Completed	USA \| SWE \| NOR \| NLD \| LBN \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| ARG	6
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT	7
NCT03064854	Phase I	Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab	PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients	Terminated	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL	3
NCT05311709	Phase II	Sotorasib	Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (SOLUCOM)	Recruiting	NOR	0
NCT02495636	Phase II	Atezolizumab + Rasdegafusp alfa	Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT05899608	Phase III	Pembrolizumab Ivonescimab	Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients	Recruiting	USA \| CAN	0
NCT02352948	Phase III	Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)	Completed	USA \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BGR \| BEL \| AUS	9
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT02696993	Phase Ib/II	Nivolumab Ipilimumab + Nivolumab	Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03647488	Phase II	Capmatinib + Spartalizumab Docetaxel	Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer	Completed	USA \| ISR \| FRA \| ESP \| DEU \| BEL	0
NCT03048136	Phase III	Ipilimumab + Nivolumab	A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)	Withdrawn	USA \| DEU \| CAN \| ARG	1
NCT06378892	Phase II	Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium Lorlatinib + Pemetrexed Disodium	A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)	Recruiting	ITA	0
NCT03505554	Phase II	Lorlatinib	A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)	Recruiting	ITA	0
NCT01744652	Phase I	Crizotinib + Dasatinib	Dasatinib and Crizotinib in Advanced Cancer	Completed	USA	0
NCT02142738	Phase III	Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium	Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)	Completed		0
NCT05570825	Phase II	Pembrolizumab + SX-682	SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT03975114	Phase II	Durvalumab + Tremelimumab Durvalumab	A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)	Recruiting	ITA	0
NCT04811001	Phase II	Dacomitinib Osimertinib	Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)	Recruiting	ITA	0
NCT03267316	Phase Ib/II	Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab	A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)	Completed	SWE \| NOR \| NLD \| LVA \| LTU \| EST \| ESP \| DNK \| DEU \| BEL \| AUT	0
NCT02965885	Phase I	Pimitespib	A Study of TAS-116 in Patients With Solid Tumors	Completed	USA \| ITA \| GBR	0
NCT04499053	Phase II	Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab	Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03275597	Phase I	Durvalumab + Tremelimumab	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	Terminated	USA	0
NCT03991819	Phase I	Binimetinib + Pembrolizumab	Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer	Recruiting	CAN	0
NCT03194893	Phase III	Crizotinib Alectinib	A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer	Recruiting	USA \| TUR \| POL \| ITA \| FRA \| ESP	4
NCT03178071	Expanded access	Lorlatinib	Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations	No longer available	USA	0
NCT02513667	Phase II	Ceritinib	Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma	Terminated	USA	0
NCT04738487	Phase III	Pembrolizumab MK-7684A	Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	Active, not recruiting	USA \| TUR \| ROU \| HUN \| CAN \| BRA	17
NCT01970865	Phase II	Lorlatinib Crizotinib	A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	5
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Active, not recruiting	USA \| NLD \| FRA \| ESP \| DNK \| BRA \| BEL \| AUS	6
NCT04270591	Phase Ib/II	SCC244	Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	Recruiting	USA	2
NCT04265534	Phase II	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium	KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)	Terminated	USA	0
NCT03164772	Phase Ib/II	BI 1361849 + Durvalumab + Tremelimumab	Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC	Completed	USA	0
NCT05144997	FDA approved	Lorlatinib	Lorlatinib Continuation Study	Active, not recruiting	USA \| FRA \| ESP	5
NCT03631199	Phase III	Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium	Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)	Active, not recruiting	USA \| TUR \| SWE \| SVK \| ROU \| POL \| NOR \| NLD \| LBN \| ITA \| ISL \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| AUT \| AUS \| ARG	15
NCT04758949	Phase II	Nivolumab FL-101 + Nivolumab FL-101	FL-101 in Surgically Resectable Non-Small Cell Lung Cancer	Withdrawn		0
NCT05597800	Phase II	Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel	Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)	Not yet recruiting	ITA	0
NCT03977194	Phase III	Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel	Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)	Active, not recruiting	FRA	0
NCT03348904	Phase III	Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium	Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer	Terminated	USA	0
NCT04274907	Phase I	Pembrolizumab + Venetoclax Pembrolizumab	A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression	Terminated	USA	0
NCT02879617	Phase II	Durvalumab	A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients	Completed	USA	0
NCT04793815	FDA approved	Pembrolizumab	Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	Completed	CAN	0
NCT02864251	Phase III	Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium	A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722)	Completed	USA \| FRA \| ESP \| CAN	6
NCT05722886	Phase II	Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)	Recruiting	GBR	0
NCT05565378	Phase II	Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab	A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| BRA \| BEL \| ARG	7
NCT03515629	Phase III	Cemiplimab + Ipilimumab Pembrolizumab	REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer	Terminated	USA \| LTU \| ITA	0
NCT04693468	Phase I	Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib	Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	Recruiting	USA	0
NCT05777603	Phase I	Aztreonam + Pembrolizumab + Vancomycin	Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT05212922	Phase II	Toripalimab-tpzi + YH001	A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)	Withdrawn	AUT \| AUS	3
NCT03996473	Phase Ib/II	Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Terminated	USA \| NLD \| ESP \| BEL	0
NCT04341181	Phase II	Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)	Recruiting	DNK	0
NCT06362369	Phase Ib/II	7HP349 + Ipilimumab + Nivolumab	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy	Recruiting	USA	0
NCT06312137	Phase III	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264	A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)	Recruiting	USA \| ROU \| POL \| NOR \| NLD \| ISR \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT05746481	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab	Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases	Recruiting	USA	0
NCT04169841	Phase II	Durvalumab + Olaparib + Tremelimumab	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR)	Active, not recruiting	FRA	0
NCT04022876	Phase I	ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium	A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)	Terminated	USA \| POL \| ITA \| ESP \| DEU	2
NCT04892472	Phase II	Pembrolizumab	EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)	Recruiting	USA	0
NCT04884282	Phase II	Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101	Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED)	Recruiting	ITA \| FRA \| ESP	0
NCT02706626	Phase II	Brigatinib	Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors	Terminated	USA	0
NCT04223596	Phase II	Brigatinib	Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)	Active, not recruiting	ESP	0
NCT04921358	Phase III	Docetaxel Sitravatinib + Tislelizumab	Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Terminated	AUS	1
NCT00585195	Phase I	Crizotinib + Itraconazole Crizotinib + Rifampin	A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)	Completed	USA \| AUS	2
NCT05815186	Phase II	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC - Phase II	Withdrawn	USA	0
NCT05398094	Phase II	Sotorasib	Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung)	Recruiting	ESP	0
NCT06522360	Phase II	Brigatinib Brigatinib + Carboplatin + Pemetrexed Disodium	Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)	Not yet recruiting	USA	0
NCT02733250	Phase Ib/II	Nab-paclitaxel + Pembrolizumab	Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)	Completed	CAN	0
NCT06120075	Phase I	AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27)	Recruiting	USA	0
NCT02400814	Phase I	Atezolizumab	MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer	Terminated	USA	0
NCT01449461	Phase Ib/II	Brigatinib	A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113	Completed		0
NCT04591431	Phase II	Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)	Active, not recruiting	ITA	0
NCT04367311	Phase II	Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Docetaxel	Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)	Recruiting	USA	0
NCT05438329	Phase Ib/II	DB-1305	First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors	Recruiting	USA	2
NCT03468985	Phase II	Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab	Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer	Completed	USA	0
NCT03999710	Phase II	Durvalumab	Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04250246	Phase II	Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab	A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)	Not yet recruiting	ITA	0
NCT02227940	Phase I	Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine	Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer	Completed	USA	0
NCT02504489	Phase III	Docetaxel Docetaxel + Plinabulin	Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)	Completed	USA \| AUS	1
NCT04140500	Phase I	RO7247669	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	TUR \| ISR \| GBR \| ESP \| DNK	5
NCT03847519	Phase Ib/II	ADXS-503 + Pembrolizumab ADXS-503	Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer	Completed	USA	0
NCT04623775	Phase II	Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab	A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT03430063	Phase II	Cemiplimab + Ipilimumab Cemiplimab	A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer	Terminated	USA \| POL \| GBR \| FRA \| ESP \| DEU \| BEL	2
NCT05715229	Phase II	Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT)	Recruiting	USA	0
NCT05769075	Phase I	TY-2136b	A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations	Recruiting	USA	0
NCT02823990	Phase II	MVA-MUC1-IL2 vaccine + Nivolumab	TG4010 and Nivolumab in Patients With Lung Cancer	Completed	USA	0
NCT03088930	Phase II	Crizotinib	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	Completed	USA	0
NCT04956692	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)	Active, not recruiting	USA \| TUR \| ROU \| POL \| HUN \| FRA \| ESP \| BRA	8
NCT03023904	Phase II	Nivolumab	Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads	Withdrawn		0
NCT05650879	Phase I	ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)	Recruiting	USA \| ITA \| FRA \| ESP \| AUS	2
NCT02041533	Phase III	Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)	Completed	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	4
NCT05384626	Phase Ib/II	NVL-655	A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	4
NCT06000358		Pembrolizumab	The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer (LUCACRIMUNO)	Recruiting	LTU	0
NCT01935336	Phase II	Ponatinib	Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers	Completed	USA	0
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| AUS	0
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT05005273	Phase II	Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab	A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Completed	USA \| TUR \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS \| ARG	1
NCT03526887	Phase II	Pembrolizumab	Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)	Completed	ESP	0
NCT03313778	Phase I	mRNA-4157 + Pembrolizumab mRNA-4157	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)	Recruiting	USA \| GBR \| AUS	1
NCT02292550	Phase Ib/II	Ceritinib + Ribociclib	Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.	Completed	USA \| ITA \| FRA \| ESP	2
NCT06116786	Phase I	Cetrelimab + JNJ-86974680	A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| ESP \| DEU	1
NCT01772797	Phase I	Ceritinib Luminespib	Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer	Completed	USA \| ITA \| ESP \| AUS	1
NCT04863248	Phase II	Docetaxel + Trilaciclib Docetaxel	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)	Terminated	USA	0
NCT05631574	Phase I	BMF-219	Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer	Recruiting	USA	1
NCT02572453	Phase II	Onalespib	Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL)	Terminated	USA	0
NCT04362072	FDA approved	Lorlatinib	Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer	Completed	USA \| POL \| ITA \| GBR \| ESP \| CHE	1
NCT05397171	Phase Ib/II	AZD8853	A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours	Terminated	USA \| CAN	0
NCT05598853	Phase I	Ipilimumab + Nivolumab	Intrathecal Double Checkpoint Inhibition (IT-IO)	Recruiting	CHE	0
NCT05687266	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)	Recruiting	USA \| TUR \| SWE \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BGR \| AUT	8
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT03178552	Phase II	Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| ISR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	14
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT03774732	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)	Active, not recruiting	FRA	1
NCT04146571	Expanded access	Ensartinib	Expanded Access to Ensartinib for Participants With ALK+ NSCLC	Available	USA	0
NCT04614103	Phase II	LN-145	Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer	Recruiting	USA \| NLD \| DEU \| CHE \| CAN	0
NCT04639245	Phase Ib/II	MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells	Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	Terminated	USA	0
NCT03611738	Phase I	Ceritinib + Docetaxel	Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC	Active, not recruiting	USA	0
NCT04311710	Phase Ib/II	Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20	A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)	Terminated	USA \| NZL \| ITA	0
NCT04866017	Phase III	Durvalumab BGBA1217 + Tislelizumab Tislelizumab	A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	Terminated	USA \| ESP \| AUS	2
NCT01121588	Phase I	Crizotinib	An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)	Terminated	USA \| ITA	5
NCT05014815	Phase II	BGBA1217 + Tislelizumab Tislelizumab	Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer	Completed	USA \| FRA \| ESP \| AUT \| AUS	2
NCT04827576	Phase II	Docetaxel + Hu5F9-G4	Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)	Terminated	USA \| POL \| GBR \| FRA \| ESP	0
NCT03829319	Phase III	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS \| ARG	5
NCT04632992	Phase II	Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib	A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)	Completed	USA	0
NCT05450562	Phase Ib/II	Atezolizumab + SAR444200 SAR444200	Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors	Recruiting	USA \| CAN	3
NCT05445843	Phase II	JDQ443	Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression >= 1% and an STK11 Co-mutation.	Active, not recruiting	USA \| TUR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUT \| ARG	5
NCT04547504	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium	PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE)	Active, not recruiting	FRA	0
NCT04467723	Phase Ib/II	Atezolizumab + Pirfenidone	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	Recruiting	USA	0
NCT02453282	Phase III	Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)	Active, not recruiting	USA \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	6
NCT04385368	Phase III	Durvalumab	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)	Completed	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG	11
NCT03703050	Phase II	Nivolumab	Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)	Recruiting	NLD \| FRA \| DNK	0
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT05240131	Phase Ib/II	Atezolizumab + GB1211	A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).	Active, not recruiting	POL \| FRA \| ESP	0
NCT03707938	Phase I	Brigatinib	Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT06096844	Phase III	Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium	Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	Recruiting	USA	0
NCT05006794	Phase I	GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies	Recruiting	USA \| ISR	0
NCT02737501	Phase III	Brigatinib Crizotinib	ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)	Completed	USA \| SWE \| NOR \| NLD \| LUX \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| AUT \| AUS	4
NCT02542293	Phase III	Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| ISR \| GRC \| GBR \| FIN \| DNK \| BRA \| BGR \| ARG	16
NCT02277457	Phase I	Crizotinib Erlotinib	Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations	Withdrawn	USA	0
NCT01579994	Phase I	Crizotinib + Ganetespib	Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers	Completed	USA	0
NCT03596866	Phase III	Brigatinib Alectinib	A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)	Completed	USA \| SWE \| ROU \| ITA \| HRV \| GRC \| FRA \| ESP \| DEU \| CAN \| AUT \| ARG	8
NCT04111705	Phase II	Lorlatinib	Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)	Active, not recruiting	FRA	0
NCT02927340	Phase II	Lorlatinib	A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions	Unknown status	USA	0
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| CAN \| AUS	4
NCT05800015	Phase II	Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel	A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| ISR \| CAN \| AUS	4
NCT05061550	Phase II	Durvalumab + Monalizumab Durvalumab + Oleclumab	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)	Recruiting	USA \| TUR \| ITA \| IRL \| HUN \| FRA \| ESP \| CAN \| BEL	3
NCT02289144	Phase II	Ceritinib	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer	Withdrawn	USA	0
NCT04929041	Phase II	Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin	Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Recruiting	USA	0
NCT05317858	Phase III	Pembrolizumab	Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets	Recruiting	USA \| CAN	1
NCT05689671	FDA approved	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Nab-paclitaxel	Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)	Recruiting	DEU	0
NCT03087448	Phase Ib/II	Ceritinib + Trametinib	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA	0
NCT04940637	Phase II	Dostarlimab-gxly + Niraparib	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)	Recruiting	ITA	0
NCT02393625	Phase I	Ceritinib + Nivolumab	Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer	Active, not recruiting	USA \| ITA \| ESP \| CAN \| BEL \| AUS	2
NCT02576574	Phase III	Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin	Avelumab in First-line NSCLC (JAVELIN Lung 100)	Completed	USA \| TUR \| SVK \| ROU \| POL \| NZL \| NLD \| LTU \| LBN \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| EST \| ESP \| DNK \| DEU \| CZE \| CYP \| CAN \| BRA \| BGR \| BEL \| AUS	14
NCT03409614	Phase III	Cemiplimab + Ipilimumab Cemiplimab	Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer	Active, not recruiting	USA \| TUR \| SVK \| ROU \| POL \| LTU \| ITA \| IRL \| GRC \| FRA \| AUT	7
NCT06472076	Phase III	Pembrolizumab Dostarlimab-gxly + EOS-448	A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)	Recruiting	TUR \| SWE \| SVN \| SVK \| ROU \| POL \| NLD \| ITA \| HUN \| HRV \| GRC \| FRA \| FIN \| EST \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| ARG	12
NCT06431633	Phase II	Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin	Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)	Not yet recruiting	ESP	0
NCT01712217	Phase Ib/II	Crizotinib Onalespib	A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib	Completed	USA \| FRA \| ESP \| CAN	1
NCT05313009	Phase Ib/II	Sotorasib + TH-4000	Tarlox and Sotorasib in Patients With KRAS G12C Mutations	Terminated	USA	0
NCT03631706	Phase II	Bintrafusp alfa Pembrolizumab	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| TUR \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	6
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT03469960	Phase III	Ipilimumab + Nivolumab	Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE)	Active, not recruiting	FRA	0
NCT04310007	Phase II	Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab	Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT03202940	Phase Ib/II	Alectinib + Cobimetinib	A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC	Active, not recruiting	USA	0
NCT06173505	Phase Ib/II	Carboplatin + Pemetrexed Disodium + XmAb20717 Carboplatin + Pembrolizumab + Pemetrexed Disodium	Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC	Recruiting	USA \| NLD \| ESP \| BEL	2
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT02264990	Phase III	Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin	Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers	Completed	USA \| TUR \| NZL \| NLD \| ISR \| HUN \| GBR \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| AUS \| ARG	5
NCT06561386	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT06074588	Phase III	Docetaxel SKB264 Pemetrexed Disodium	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	10
NCT05742607	Phase II	Cisplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Paclitaxel	IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)	Recruiting	USA \| POL \| HUN \| GRC \| FRA	0
NCT03696212	Phase Ib/II	Grapiprant + Pembrolizumab	Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma	Terminated	USA	0
NCT04262375	Phase II	Durvalumab + Oleclumab	A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)	Withdrawn	CAN	0
NCT03308942	Phase II	Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib	Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	Completed	USA	0
NCT04526691	Phase I	Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)	Active, not recruiting	USA \| ITA \| ESP	2
NCT03993873	Phase Ib/II	Elzovantinib	Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)	Active, not recruiting	USA \| FRA \| ESP	1
NCT04139317	Phase II	Capmatinib + Pembrolizumab Pembrolizumab	Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50%	Terminated	NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS	6
NCT03256136	Phase II	Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab	A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer	Completed	USA	0
NCT05624996	Phase III	Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03709147	Phase II	Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium	Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME)	Unknown status	ITA	0
NCT03317496	Phase II	Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium	Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies	Terminated	USA \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| AUS	0
NCT05877430	Phase Ib/II	CJRB-101 + Pembrolizumab	Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer	Recruiting	USA	1
NCT04292119	Phase Ib/II	Binimetinib + Lorlatinib Crizotinib + Lorlatinib	Lorlatinib Combinations in Lung Cancer	Unknown status	USA	0
NCT03270176	Phase I	Avelumab + Xevinapant	A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy	Completed	ROU \| POL \| CAN	0
NCT03559049	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib	Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT05255302	Phase II	Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)	Recruiting	FRA	0
NCT03131206	Phase Ib/II	Alectinib	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer	Terminated	USA	0
NCT06357533	Phase III	Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Recruiting	USA \| TUR \| POL \| ITA \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS	6
NCT02271139	Phase III	Alectinib	Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib	No longer available	USA	0
NCT04013542	Phase I	Ipilimumab + Nivolumab Nivolumab	Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Active, not recruiting	USA	0
NCT05077709	Phase II	IO102-IO103 + Pembrolizumab	IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	Active, not recruiting	USA \| GBR \| ESP	0
NCT05358548	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab	ATATcH Alternating Treatment Plans for Advanced Cancer	Recruiting	USA	0
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient With Poor General Condition (SAVIMMUNE)	Active, not recruiting	FRA	0
NCT04625699	Phase II	Durvalumab + Tremelimumab	Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment	Withdrawn		0
NCT06236438	Phase II	ABBV-151 + Budigalimab + Cisplatin + Pemetrexed Disodium Budigalimab + Carboplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ABBV-151 + Budigalimab + Carboplatin + Pemetrexed Disodium ABBV-151 + Budigalimab + Pemetrexed Disodium Budigalimab + Cisplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium	Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)	Recruiting	USA \| TUR \| ISR \| AUS	3
NCT03793179	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	Active, not recruiting	USA \| CAN	1
NCT04849273	Phase Ib/II	TPX-0131	A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC	Terminated	USA \| AUS	1
NCT05541822	Phase II	ABN401	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	Recruiting	USA	2
NCT03535740	Phase II	Brigatinib	A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)	Completed	USA \| SWE \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| AUT \| AUS	5
NCT05858164	Phase I	BAY2862789	A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors	Recruiting	USA \| ISR \| ESP \| AUS	3
NCT04895579	Phase I	Copanlisib + Durvalumab	Lung Cancer With Copanlisib and Durvalumab (LCD)	Active, not recruiting	USA	0
NCT04716946	Phase II	Durvalumab	Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy	Recruiting	USA	0
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Recruiting	FRA	0
NCT03093116	Phase Ib/II	Repotrectinib	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Recruiting	USA \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT05501665	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	Recruiting	USA	0
NCT05935774	Phase II	Atezolizumab + Trabedersen	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT02568267	Phase II	Entrectinib	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	6
NCT03665129	Phase I	Avdoralimab + Durvalumab	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)	Terminated	USA \| FRA	0
NCT06088771	Phase Ib/II	Cemiplimab + Dupilumab	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	Recruiting	USA	0
NCT02336451	Phase II	Ceritinib	A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges	Completed	USA \| TUR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS	5
NCT04227028	Phase I	Bevacizumab + Brigatinib	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	Active, not recruiting	USA	0
NCT03268057	Phase Ib/II	Avelumab + Pepinemab	VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer	Completed	USA	0
NCT03591731	Phase II	Nivolumab Ipilimumab + Nivolumab	Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)	Active, not recruiting	FRA	0
NCT06532032	Phase Ib/II	Amivantamab-vmjw + Docetaxel	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail)	Recruiting	USA \| TUR	1
NCT05882734	Phase Ib/II	Cemiplimab + M1774	Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| BEL	2
NCT04634110	Phase II	Brigatinib	Brigatinib Before Brain Irradiation Trial (B3i Trial)	Terminated	USA	0
NCT03516981	Phase II	MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)	Active, not recruiting	USA \| POL \| ITA \| IRL \| GBR \| ESP \| CHE \| CAN \| AUS	7
NCT05633667	Phase II	Etrumadenant + Sacituzumab govitecan-hziy + Zimberelimab Carboplatin + Paclitaxel + Zimberelimab Carboplatin + Nab-paclitaxel + Zimberelimab Docetaxel Etrumadenant + Zimberelimab Cisplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pemetrexed Disodium + Zimberelimab AB154 + Sacituzumab govitecan-hziy + Zimberelimab AB154 + Etrumadenant + Zimberelimab Sacituzumab govitecan-hziy	Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)	Recruiting	USA \| ISR \| GBR \| BRA	3
NCT02554812	Phase Ib/II	Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab	A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)	Terminated	USA \| POL \| GBR \| FRA \| CAN \| AUS	2
NCT03220477	Phase I	Guadecitabine + Mocetinostat + Pembrolizumab	Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.	Active, not recruiting	USA	0
NCT04198766	Phase I	INBRX-106 INBRX-106 + Pembrolizumab	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)	Recruiting	USA	0
NCT02259114	Phase I	Birabresib	A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors	Completed		0
NCT05925530	Phase II	Durvalumab	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)	Recruiting	USA \| SWE \| ITA \| HUN \| FRA \| ESP \| DEU \| CZE \| CAN \| AUT	1
NCT05770037	Phase II	Alectinib	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)	Recruiting	GBR	0
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05401786	Phase II	Cemiplimab Ipilimumab	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)	Recruiting	NLD	0
NCT05757492	Phase Ib/II	CHS-006 + Toripalimab-tpzi	Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Terminated	USA	0
NCT03371381	Phase Ib/II	JNJ-64041757 + Nivolumab Nivolumab	An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung	Terminated	USA \| ESP \| BEL	0
NCT03896074	Phase II	Atezolizumab + Bevacizumab Atezolizumab	Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT)	Unknown status	ITA	0
NCT04450901	Phase I	YBL-006	Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors	Active, not recruiting	AUS	2
NCT01798485	Phase III	Ganetespib Docetaxel	A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC	Terminated	USA \| SVN \| ROU \| POL \| NLD \| ITA \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	5
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))	Recruiting	USA	1
NCT03003962	Phase III	Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel	Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)	Active, not recruiting	USA \| TUR \| POL \| NLD \| HUN \| AUS	6
NCT06161441	Phase II	Carboplatin + Cemiplimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Paclitaxel Cemiplimab + Fianlimab Cemiplimab + Cisplatin + Paclitaxel Cemiplimab + Cisplatin + Pemetrexed Disodium Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Fianlimab + Paclitaxel	A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery	Recruiting	USA \| AUS	2
NCT02521051	Phase Ib/II	Bevacizumab Alectinib	Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer	Unknown status	USA	0
NCT03417037	Phase III	Linrodostat + Nivolumab	An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA \| TUR \| ITA \| GRC \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| AUT \| AUS	4
NCT06472245	Phase III	OSE 2101 Docetaxel	Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)	Not yet recruiting	USA	0
NCT05117242	Phase II	GEN1046 + Pembrolizumab GEN1046	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	1
NCT04263051	Phase II	Nivolumab + UCPVax	Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax)	Active, not recruiting	FRA	0
NCT05785767	Phase II	Cemiplimab Cemiplimab + Fianlimab	A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| ISR \| CAN \| AUS	5
NCT02382406	Phase Ib/II	Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC	Terminated	USA	0
NCT05987644	Phase Ib/II	Alectinib	Delayed or Upfront Brain RAdiotherapy in Treatment naive Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE)	Recruiting	USA	0
NCT02451865	Phase I	Binimetinib + Docetaxel	Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer	Withdrawn	USA	0
NCT04837716	Phase I	Bevacizumab + Carboplatin + Ensartinib + Pemetrexed Disodium	Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT01784640	Phase I	Luminespib + Pemetrexed Disodium	Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer	Completed	USA	0
NCT01772004	Phase I	Avelumab	Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)	Completed	USA \| POL \| GBR \| FRA \| DEU \| CZE \| BEL	2
NCT03322540	Phase II	Pembrolizumab Epacadostat + Pembrolizumab	Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)	Completed	USA \| TUR \| POL \| ITA \| ISR \| IRL \| GBR \| EST \| ESP \| DNK \| CHE \| CAN \| AUS	5
NCT02654587	Phase III	OSE 2101 Pemetrexed Disodium Docetaxel	Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1)	Terminated	USA \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE	0
NCT03158883	Phase I	Avelumab	UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients	Completed	USA	0
NCT02864992	Phase II	Tepotinib	Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUT	4
NCT03904108	Phase II	Ramucirumab	Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy	Terminated	USA	0
NCT04263090	Phase Ib/II	Nivolumab + Rigosertib	Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment	Completed	USA	0
NCT04267848	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial	Recruiting	USA	1
NCT02314364	Phase II		A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC	Completed	USA	0
NCT04105270	Phase II	Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	Recruiting	USA	0
NCT02422589	Phase I	Warfarin Midazolam Ceritinib	A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors	Completed	USA \| ITA \| ESP \| DNK	0
NCT06099782	Phase II	MK-3475A Pembrolizumab	A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)	Recruiting	USA \| TUR \| POL \| NZL \| FRA \| AUS \| ARG	3
NCT05703555	Phase II	SAR408701	INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION)	Withdrawn	NLD	0
NCT05132075	Phase III	JDQ443 Docetaxel	Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)	Active, not recruiting	USA \| TUR \| SVN \| ROU \| LBN \| ITA \| ISL \| HUN \| GRC \| FIN \| ESP \| CAN \| AUS \| ARG	12
NCT05815173	Phase I	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC	Recruiting	USA	0
NCT03786692	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium	Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC	Recruiting	USA	0
NCT05007769	Phase II	Atezolizumab + Nogapendekin alfa inbakicept + Ramucirumab	Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)	Withdrawn		0
NCT03625323	Phase II	Eftilagimod alpha + Pembrolizumab	Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)	Active, not recruiting	USA \| GBR \| ESP \| AUS	1
NCT03215706	Phase III	Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab	A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)	Active, not recruiting	USA \| ROU \| POL \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	5
NCT03130764	Phase II	Durvalumab + Tremelimumab	Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC	Withdrawn		0
NCT02185690	Phase I	Binimetinib + Carboplatin + Pemetrexed Disodium	A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung	Completed	CAN	0
NCT03425331	Phase II	Ipilimumab + Nivolumab	Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC	Terminated	USA	0
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Active, not recruiting	USA \| CAN	3
NCT05984277	Phase III	Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)	Recruiting	USA \| TUR \| SVK \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT02350764	Phase II	Ipilimumab + Nivolumab	Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs	Completed	USA	0
NCT04561362	Phase Ib/II	BT8009 BT8009 + Pembrolizumab	Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CAN	0
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT03472560	Phase II	Avelumab + Axitinib	A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)	Terminated	USA \| POL \| ITA \| HUN \| ESP	3
NCT05012254	Phase II	Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium	Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)	Active, not recruiting	ESP	0
NCT03664024	Phase II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)	Completed	USA \| ISR \| HUN \| ESP \| CAN	0
NCT03838159	Phase II	Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel	NADIM II: Neo-Adjuvant Immunotherapy (NADIMII)	Active, not recruiting	ESP	0
NCT01803282	Phase I	Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab	Safety and Tolerability Study in Solid Tumors	Completed	USA	0
NCT04318938	Phase II	Brigatinib	Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping	Active, not recruiting	DEU	0
NCT05709821	Phase Ib/II	Pembrolizumab IMM60 IMM60 + Pembrolizumab	IMM60 and Pembrolizumab in Melanoma and NSCLC	Terminated	USA \| GBR \| ESP	0
NCT05215340	Phase III	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT03425006	Phase II	Itacitinib + Pembrolizumab	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	Terminated	USA	0
NCT02094573	Phase II	Brigatinib	A Phase 2, Multicenter, Randomized Study of AP26113	Completed		0
NCT02473497	Expanded access	Crizotinib	Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients	No longer available	USA	0
NCT03520686	Phase III	Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab	QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.	Active, not recruiting	USA	0
NCT04856176	Phase II	Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim	A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy	Recruiting	USA	0
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT02091141	Phase II	Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Completed	USA	0
NCT04033354	Phase III	Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel	A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC	Active, not recruiting	USA \| TUR \| POL	4
NCT02784158	Phase I	Brigatinib	An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer	No longer available	USA	0
NCT05015010	Phase II	Alectinib	Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO)	Active, not recruiting	ITA	0
NCT05493566	Phase I	Aldesleukin + Pembrolizumab	Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04151563	Phase Ib/II	Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab	A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy	Withdrawn	USA \| ROU \| POL \| NOR \| NLD \| GRC \| DNK \| BEL \| ARG	1
NCT04427072	Phase III	Docetaxel Capmatinib	Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)	Completed	NLD \| ITA \| FRA \| ESP \| DEU \| BRA \| BEL	3
NCT02395172	Phase III	Avelumab Docetaxel	Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)	Completed	USA \| TUR \| SVK \| ROU \| POL \| ITA \| ISR \| HUN \| HRV \| GBR \| FRA \| ESP \| DNK \| CZE \| CHE \| BRA \| BGR \| BEL \| AUS \| ARG	9
NCT06680050	Phase II	Ceralasertib + Durvalumab	Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL) (AUSTRAL)	Not yet recruiting	ITA \| CHE	0
NCT06331455	Phase II	Durvalumab	Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)	Recruiting	CAN	0
NCT04127110	Phase II	Lorlatinib	Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)	Active, not recruiting	NOR \| NLD \| GBR \| FRA \| ESP \| BEL	1
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer	Recruiting	USA	0
NCT05005403	Phase I	ABBV-514 + Budigalimab ABBV-514	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab	Recruiting	USA \| ISR	3
NCT02848651	Phase II	Atezolizumab	A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST]	Completed	USA	0
NCT04585477	Phase II	Durvalumab	Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)	Recruiting	USA	0
NCT06627647	Phase III	AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	Not yet recruiting	USA \| TUR \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	7
NCT04005144	Phase I	Binimetinib + Brigatinib	Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer	Terminated	USA	0
NCT05836324	Phase I	INCA33890	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| CHE	0
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Active, not recruiting	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT05000710	Phase II	Durvalumab Durvalumab + Tremelimumab Tremelimumab	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)	Recruiting	ISR	0
NCT03156114	Phase I	Ezabenlimab Miptenalimab	This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.	Completed	USA \| POL \| GBR \| ESP \| CAN	0
NCT03345810	Phase II	Gemcitabine + Vinorelbine Carboplatin + Nab-paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Durvalumab + Gemcitabine + Vinorelbine	Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION)	Completed	DEU	0
NCT05064280	Phase II	Lenvatinib Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT05200481	Phase II	Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Active, not recruiting	FRA	0
NCT05840770	Phase II	Cemiplimab	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05557591	Phase II	Cemiplimab BNT116 + Cemiplimab	A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)	Recruiting	USA \| TUR \| ESP \| DEU	3
NCT05555732	Phase III	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT03953235	Phase Ib/II	GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab	A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens	Completed	USA	0
NCT03286296	Phase I	LZM009	LZM009 to Treat Patients With Advanced Solid Tumors	Completed	USA	0
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT02595944	Phase III	Nivolumab	Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)	Active, not recruiting	USA	0
NCT03302234	Phase III	Pembrolizumab Ipilimumab + Pembrolizumab	Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)	Completed	USA \| TUR \| POL \| LVA \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS \| ARG	9
NCT03965468	Phase II	Carboplatin + Durvalumab + Paclitaxel	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)	Recruiting	NLD \| ITA \| ESP \| CHE	0
NCT06635824	Phase III	Docetaxel GEN1046 + Pembrolizumab	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)	Recruiting	USA	0
NCT03166631	Phase I	BI 891065 + Ezabenlimab BI 891065	A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Terminated	USA	0
NCT02578680	Phase III	Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)	Completed		0
NCT03322566	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium	A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)	Completed	USA \| TUR \| ITA \| ISR \| IRL \| HUN \| GBR \| ESP \| CAN \| AUS	4
NCT05525338	FDA approved	Alectinib	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)	Recruiting	NLD \| FRA	0
NCT04323436	Phase II	Capmatinib + Spartalizumab Capmatinib	Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations	Terminated	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL	2
NCT04725188	Phase II	Docetaxel Docetaxel + MK-7684A MK-7684A	Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)	Completed	USA \| POL \| ITA \| ISR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	5
NCT03840902	Phase II	Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)	Terminated	USA \| NLD \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	4
NCT03456076	Phase III	Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine	A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer	Active, not recruiting	USA \| TUR \| ROU \| POL \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| AUT \| AUS	12
NCT02259582	Phase II	Carboplatin + Pemetrexed Disodium Demcizumab	A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer	Completed	USA \| ITA \| ESP \| BEL \| AUS	0
NCT04231877	Phase I	Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	USA	0
NCT05948462	Phase II	Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium	Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC)	Withdrawn	USA	0
NCT02544633	Phase II	Glesatinib	Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET	Completed	USA \| POL \| ITA \| HUN \| GBR \| CAN \| AUS	2
NCT03083691	Phase II	Ipilimumab + Nivolumab	BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer	Completed	DEU	0
NCT04644315	Phase II	Alectinib	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)	Terminated	USA	0
NCT05170204	Phase III	Durvalumab Alectinib Pralsetinib Entrectinib	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| SWE \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS	11
NCT04294810	Phase III	Atezolizumab Atezolizumab + Tiragolumab	A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| ESP \| DNK \| DEU \| CHE \| BRA \| AUT \| AUS	10
NCT03755102	Phase I	Dacomitinib	A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Completed	USA	0
NCT02314481	Phase II	Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)	Active, not recruiting	GBR	0
NCT04512430	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium	Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	Terminated	ESP	0
NCT03164616	Phase III	Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)	Active, not recruiting	USA \| POL \| HUN \| GBR \| DEU \| BRA \| BGR	12
NCT04585815	Phase Ib/II	Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591	Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)	Active, not recruiting	USA \| GBR \| BEL \| AUS	1
NCT06625775	Phase I	BBO-10203 + Trastuzumab BBO-10203	Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)	Recruiting	USA	0
NCT03775486	Phase II	Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine	Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)	Active, not recruiting	USA \| POL \| NLD \| HUN \| GBR \| BEL	6
NCT06564844	Phase III	Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)	Recruiting	USA \| TUR \| SWE \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL	7
NCT04211337	Phase III	Vandetanib Cabozantinib Selpercatinib	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS	5
NCT02657434	Phase III	Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium	A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)	Completed	USA \| ROU \| NLD \| LVA \| LTU \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| BGR \| BEL \| AUT \| AUS \| ARG	10
NCT06275360	Phase II	Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL)	Recruiting	USA	0
NCT04923126	Phase Ib/II	PD-0325901	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT00939770	Phase Ib/II	Crizotinib	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	USA \| CAN	0
NCT04484142	Phase II	Datopotamab deruxtecan	Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)	Active, not recruiting	USA \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU	3
NCT05825625	Phase II	Atezolizumab + Tiragolumab	NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing	Recruiting	DEU	0
NCT02587650	Phase II	Ceritinib Capmatinib Regorafenib Entrectinib	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	USA	0
NCT05383001	Phase II	Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine	Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)	Withdrawn	DEU	0
NCT05798663	Phase II	Atezolizumab Atezolizumab + Tiragolumab	Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC	Recruiting	USA	0
NCT04644237	Phase II	Trastuzumab deruxtecan	Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Completed	USA \| NLD \| ITA \| FRA \| ESP \| CAN \| AUS	3
NCT04655976	Phase II	Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly	Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	6
NCT03107988	Phase I	Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib	NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)	Active, not recruiting	USA \| GBR \| FRA \| CAN	0
NCT04589845	Phase II	Alectinib Divarasib Entrectinib RP-3500	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Recruiting	USA \| POL \| NZL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| BEL \| AUS	10
NCT05816252	Phase II	Osimertinib + SKB264 Carboplatin + SKB264 Carboplatin + Pembrolizumab + SKB264 Pembrolizumab + SKB264	A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	Recruiting	TUR \| ROU \| ESP	3
NCT04467801	Phase II	Ipatasertib Docetaxel + Ipatasertib	Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)	Recruiting	USA	0
NCT04776447	Phase II	Atezolizumab + Carboplatin + Paclitaxel	Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)	Active, not recruiting	ESP	0
NCT05004116	Phase Ib/II	Irinotecan + Repotrectinib + Temozolomide	A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer	Recruiting	USA	0
NCT03906071	Phase III	Docetaxel Nivolumab + Sitravatinib	Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)	Active, not recruiting	USA \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL	0
NCT04619797	Phase II	Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab	A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| BEL	7
NCT03970746	Phase Ib/II	PDClung01 + Pembrolizumab PDClung01 + Pemetrexed Disodium PDC*lung01	Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC	Active, not recruiting	POL \| NLD \| FRA \| DEU \| BEL	0
NCT02925234	Phase II	Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT03391869	Phase III	Ipilimumab + Nivolumab	Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT00932451	Phase II	Crizotinib	An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene	Completed	USA \| SWE \| POL \| NLD \| ITA \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| AUS	6
NCT06031688	Phase II	Tepotinib Ramucirumab + Tepotinib	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT02154490	Phase II	Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	Completed	USA \| CAN	0
NCT05171777	Phase II	Atezolizumab	A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer	Completed	USA \| POL \| LVA \| ITA \| FIN \| ESP \| CAN \| BRA \| ARG	3
NCT04526782	Phase II	Docetaxel Binimetinib + Encorafenib	ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)	Recruiting	FRA	0
NCT06267001	Phase III	Atezolizumab Atezolizumab + Tiragolumab	A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)	Active, not recruiting	USA \| TUR \| SVK \| POL \| ITA \| FRA \| ESP \| BRA \| AUS \| ARG	6
NCT04892953	Phase II	Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab	Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy	Recruiting	USA	0
NCT06333899	Phase I	Lorlatinib Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine Sulfate Carboplatin + Cyclophosphamide + Etoposide + Lorlatinib + Methotrexate + Vincristine Sulfate	Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Not yet recruiting	USA \| NLD \| DEU \| CAN \| AUS	0
NCT03191786	Phase III	Atezolizumab Gemcitabine Vinorelbine	A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS)	Completed	SVK \| ROU \| POL \| LUX \| ITA \| IRL \| GBR \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| ARG	7
NCT03066661	Expanded access	Entrectinib	Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions	No longer available	USA	0
NCT06225427	Phase I	Gilteritinib	Gilteritinib for the Treatment of ALK NSCLC	Recruiting	USA	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT06495125	Phase II	Defactinib + Nivolumab + RO5126766	Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05650203	Phase I	JS006 + JS009 + Toripalimab-tpzi JS009	A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies	Withdrawn		0
NCT06008093	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)	Recruiting	USA	0
NCT05364645	Phase II	Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib	Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer	Withdrawn	USA	0
NCT03037385	Phase Ib/II	Pralsetinib	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	5
NCT06623656	Phase II	Cemiplimab	Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	Not yet recruiting	USA	0
NCT02097810	Phase I	Entrectinib	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)	Completed	USA	1
NCT02949843	Phase II	Nivolumab + Pembrolizumab	Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Terminated	USA	0
NCT05417321	Phase Ib/II	HB0036	A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors	Recruiting	USA	1
NCT06083857	Phase Ib/II	Amivantamab-vmjw + Tepotinib	PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03255083	Phase I	DS-1205c + Osimertinib	DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer	Terminated		1
NCT03420508	Phase II	Ensartinib	Treating Patients With Melanoma and ALK Alterations With Ensartinib	Active, not recruiting	USA	0
NCT05153408	Phase Ib/II	BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Terminated	USA	0
NCT04832854	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer	Active, not recruiting	USA \| ESP \| CHE \| AUS	1
NCT04774718	Phase Ib/II	Alectinib	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| AUS	2
NCT03915951	Phase II	Binimetinib + Encorafenib	An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer	Active, not recruiting	USA \| NLD \| ITA \| ESP	1
NCT04094610	Phase Ib/II	Repotrectinib	A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| CAN \| AUS	3
NCT06067776	Phase I	Cetuximab + Osimertinib + Tucatinib	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	Not yet recruiting	USA	0
NCT05718297	Phase II	Brigatinib Durvalumab	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)	Withdrawn	POL \| ITA \| GBR \| FRA \| ESP	0
NCT04471428	Phase III	Docetaxel Atezolizumab + Cabozantinib	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)	Active, not recruiting	USA \| POL \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS	4
NCT03213652	Phase II	Ensartinib	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Recruiting	USA \| CAN \| AUS	1
NCT05845671	Phase Ib/II	Amivantamab-vmjw	Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations	Recruiting	USA	0
NCT02134886	Phase I	Erlotinib	Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection	Terminated	USA	0
NCT04925609	Phase Ib/II	Brigatinib	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED)	Recruiting	NLD \| FRA	0
NCT04581824	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium	Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| ITA \| FRA \| ESP \| DEU \| BRA \| ARG	3
NCT03639714	Phase Ib/II	GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab	A Study of a Personalized Neoantigen Cancer Vaccine	Completed	USA \| AUS	0
NCT04302025	Phase II	Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib	A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05781308	Phase II	Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel	Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)	Active, not recruiting	FRA	0
NCT04268550	Phase II	Selpercatinib	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)	Active, not recruiting	USA	0
NCT03057106	Phase II	Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium	Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC	Active, not recruiting	CAN \| AUS	0
NCT02650401	Phase I	Entrectinib	Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	4
NCT04541407	Phase I	Osimertinib + Temozolomide Lorlatinib + Temozolomide	Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease	Completed	USA	0
NCT04746924	Phase III	Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab	A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DEU \| BRA \| AUS \| ARG	9
NCT06007937	Phase Ib/II	Lorlatinib + Ramucirumab	A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer	Recruiting	USA	0
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG	4
NCT05775289	Phase II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669	A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer	Active, not recruiting	USA \| TUR \| ITA \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS	2
NCT05435846	Phase I	Capmatinib + Trametinib	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Terminated	USA	0
NCT04612751	Phase I	Datopotamab deruxtecan + Durvalumab AZD2936 + Carboplatin + Datopotamab deruxtecan AZD2936 + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + MEDI5752 Carboplatin + Datopotamab deruxtecan + MEDI5752	Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Recruiting	USA \| TUR \| POL \| ITA \| FRA \| ESP \| BEL	3
NCT06162572	Phase Ib/II	Cemiplimab + S095029 Cemiplimab + Sym024 Cemiplimab + Sym023 Cemiplimab	Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)	Recruiting	USA \| ROU \| ITA \| HUN \| GBR \| FRA \| ESP \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT04736173	Phase III	Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab	Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)	Active, not recruiting	USA \| TUR \| GRC	9
NCT05671510	Phase III	ONC-392 Docetaxel	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)	Recruiting	USA \| TUR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT04047862	Phase I	BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab	Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors	Completed	USA \| NZL \| AUS	3
NCT04267237	Phase II	Atezolizumab + Autogene cevumeran Atezolizumab	A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer	Withdrawn		0
NCT03868423	Phase II	Brigatinib	Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	Withdrawn	USA	0
NCT04513925	Phase III	Atezolizumab + Tiragolumab Durvalumab	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)	Active, not recruiting	USA \| TUR \| POL \| NZL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT03334617	Phase II	Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab	Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)	Active, not recruiting	USA \| ISR \| FRA \| ESP \| DEU \| CAN \| AUT	1
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT06465329	Phase II	Cemiplimab + REGN7075 REGN7075 Cemiplimab	A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA	0
NCT03563716	Phase II	Atezolizumab + Tiragolumab Atezolizumab	A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Active, not recruiting	USA \| FRA \| ESP	3
NCT05513703	Phase II	Telisotuzumab vedotin	A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA \| ITA \| ISR \| FRA \| DEU \| AUS	3
NCT03366766	Phase II	Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium	Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery	Completed	USA	0
NCT05681780	Phase Ib/II	Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs	Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC	Recruiting	USA	0
NCT05467748	Phase Ib/II	Tazemetostat	EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	Not yet recruiting	USA	0
NCT03679767	Phase II	Retifanlimab	A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	Completed	USA \| ROU \| POL \| ITA \| HUN \| FRA \| ESP \| AUT	0
NCT02638909	Phase II	Ceritinib	Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies	Terminated	USA	0
NCT03181308	Phase I	Carotuximab + Nivolumab	Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC	Completed	USA	0
NCT03456063	Phase III	Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium	A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)	Active, not recruiting	USA \| SWE \| SVN \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| AUT \| AUS	9
NCT05082610	Phase I	HMBD-002 HMBD-002 + Pembrolizumab	A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab	Recruiting	USA	0
NCT04222972	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)	Active, not recruiting	USA \| TUR \| SWE \| POL \| NOR \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUS \| ARG	6
NCT04166487	Phase II	Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium	Plasma-Adapted First-Line Pembro In NSCLC	Active, not recruiting	USA	0
NCT02299505	Phase I	Ceritinib	Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| TUR \| POL \| NLD \| LBN \| ITA \| GRC \| GBR \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS	7
NCT03052608	Phase III	Lorlatinib Crizotinib	A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS \| ARG	9
NCT02767804	Phase III	Crizotinib Ensartinib	eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	4
NCT01979536	Phase II	Crizotinib	Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma	Completed	USA	0
NCT05800366	Phase II	Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	Recruiting	USA	0
NCT02463994	Phase I	Atezolizumab	A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC	Completed	USA	0
NCT04676360	Phase II	belantamab mafodotin-blmf	Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma	Recruiting	USA	0
NCT02343679	Phase II	Ceritinib	Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies	Withdrawn	USA	0
NCT01837329	Phase I	Tetrathiomolybdate	Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer	Completed	USA	0
NCT02232516	Phase II	Lenalidomide + Romidepsin	Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma	Active, not recruiting	USA	0
NCT04334174	Phase II	Brentuximab vedotin	Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T)	Withdrawn	USA	0
NCT03719898	Phase II	Brigatinib	Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma	Withdrawn	USA	0
NCT06072131	Phase III	Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Cyclophosphamide + Pralatrexate + Prednisone + Vincristine Sulfate Belinostat + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate	To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO)	Recruiting	USA \| POL \| HUN	2
NCT04163432	Phase II	Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium	Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (STAGGER)	Recruiting	USA	0
NCT02342782	Phase I	Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab	Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT02048488	Phase Ib/II	Belizatinib	A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas	Completed	USA \| POL \| GBR \| ESP	1
NCT02511184	Phase I	Crizotinib Pembrolizumab	Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients	Terminated	USA	0
NCT02584933	FDA approved	Ceritinib	Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study	Active, not recruiting	USA \| POL \| LBN \| ITA \| FRA \| ESP \| DEU \| CZE \| BRA \| BGR \| BEL \| AUS	9
NCT01947608	Phase I	Ceritinib	Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC	No longer available	USA \| ARG	8
NCT03626545	Phase III	Canakinumab + Docetaxel Docetaxel	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)	Terminated	USA \| POL \| NLD \| LBN \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	8
NCT02075840	Phase III	Alectinib Crizotinib	A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| AUS	16
NCT05820841	Phase III	Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate	Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED)	Recruiting	DEU	0
NCT03696784	Phase I	Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK	Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	Recruiting	USA	0
NCT02281409	Phase Ib/II	Mogamulizumab	Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors	Completed	USA	0
NCT02605746	Phase I	Ceritinib	Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis	Completed	USA	0
NCT02134912	Phase II	Crizotinib + Pemetrexed Disodium Pemetrexed Disodium	S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib	Terminated	USA	0
NCT02681302	Phase Ib/II	Ipilimumab + Nivolumab	Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)	Terminated	USA	0
NCT03586999	Phase Ib/II	Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate	Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas	Completed	USA	0
NCT02797470	Phase Ib/II	Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan	Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	Active, not recruiting	USA	0
NCT02729961	Phase Ib/II	Brentuximab vedotin + Ceritinib	Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma	Withdrawn	USA	0
NCT01828112	Phase III	Docetaxel Pemetrexed Disodium Ceritinib	LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib	Completed	USA \| TUR \| NLD \| LBN \| ITA \| ISR \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL	6
NCT03570892	Phase III	Lenalidomide Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Carmustine + Cytarabine + Etoposide + Melphalan Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cyclophosphamide + Fludarabine + Tisagenlecleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab Gemcitabine + Oxaliplatin + Rituximab Bendamustine + Fludarabine + Tisagenlecleucel	Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)	Active, not recruiting	USA \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS	5
NCT04824092	Phase III	Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)	Active, not recruiting	USA \| TUR \| SVK \| ROU \| POL \| NZL \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| AUT \| AUS \| ARG	10
NCT04882163	Phase Ib/II	Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma	Withdrawn	USA \| GBR \| FRA \| ESP \| BEL \| AUT	2
NCT04002947	Phase II	Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate	Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma	Recruiting	USA	0
NCT06311721	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab ABP 234 + Cisplatin + Pemetrexed Disodium ABP 234 + Carboplatin + Pemetrexed Disodium ABP 234 + Pemetrexed Disodium	A Study to Compare ABP 234 and Keytruda (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	Recruiting	USA \| ROU \| POL \| ITA \| HUN \| ESP \| BGR	5
NCT06667154	Phase II	Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy	Recruiting	BRA	0
NCT03274492	Phase III	Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate	A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT02321501	Phase I	Ceritinib + Everolimus	Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03382912	Phase II	Nivolumab + Pegilodecakin Nivolumab	Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2)	Terminated	USA	0
NCT05567055	Phase II	Capmatinib	Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations	Withdrawn		0
NCT01829217	Phase II	Sunitinib	Sunitinib in Never-Smokers With Lung Adenocarcinoma	Completed	USA	0
NCT02710396	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Genetic Predictors of Benefit to Pembrolizumab	Terminated	USA	0
NCT04000529	Phase I	Spartalizumab + TNO155 Ribociclib + TNO155	Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Terminated	USA \| ESP \| DEU \| BEL \| AUS	4
NCT04434560	Phase II	Ipilimumab + Nivolumab	Neoadjuvant Immunotherapy in Brain Metastases	Terminated	USA	0
NCT01625234	Phase Ib/II	Ensartinib	Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer	Completed	USA	0
NCT02186821	Phase II	Ceritinib	Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)	Terminated	USA	0
NCT03075553	Phase II	Nivolumab	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Terminated	USA	0
NCT03905135	Phase I	Avelumab + rhIL-15	Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies	Completed	USA	0
NCT02663297	Phase I	ATLCAR.CD30 cells	Administration of T Lymphocytes for Prevention of Relapse of Lymphomas	Active, not recruiting	USA	0
NCT04609566	Phase II	Brentuximab vedotin + Pembrolizumab	Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors	Recruiting	USA \| CAN	0
NCT02546986	Phase II	Azacitidine + Pembrolizumab Pembrolizumab	Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer	Active, not recruiting	USA \| ITA \| GRC \| FRA \| ESP \| DEU	0
NCT04564157	Phase III	Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel	New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT)	Active, not recruiting	ESP	0
NCT05565417	Phase Ib/II	IMT-009	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	USA	0
NCT01877083	Phase II	Lenvatinib	Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung	Completed	USA	4
NCT04093167	Phase II	Pembrolizumab	Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC	Recruiting	USA \| CAN	0
NCT03138889	Phase Ib/II	NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium	Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors	Terminated	USA \| FRA \| ESP \| DEU \| AUS	0
NCT01752400	Phase II	Luminespib	AUY922 for Advanced ALK-positive NSCLC	Completed	USA	0
NCT01998126	Phase I	Erlotinib + Ipilimumab Crizotinib + Ipilimumab	Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts	Completed	USA	0
NCT05221840	Phase III	Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab	A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)	Recruiting	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS	11
NCT06449313	Phase II	Cemiplimab	Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement (NEO-SURG)	Not yet recruiting	USA	0
NCT04266730	Phase I	PANDA-VAC + Pembrolizumab + Poly ICLC	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	Not yet recruiting	USA	0
NCT02387216	Phase II	Seribantumab Pemetrexed Disodium Docetaxel	A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC	Terminated	USA \| HUN \| FRA \| ESP \| DEU \| CAN	0
NCT05403385	Phase II	Carboplatin + EOS100850 + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer	Recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL	0
NCT05450692	Phase III	Docetaxel Ceralasertib + Durvalumab	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)	Active, not recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	7
NCT05487235	Phase I	Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Recruiting	USA \| POL \| NZL \| ESP \| CAN \| BRA \| AUS \| ARG	2
NCT01742286	Phase I	Ceritinib	Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	1
NCT04705818	Phase II	Durvalumab + Tazemetostat	Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE)	Recruiting	FRA	0
NCT05378763	Phase III	Poziotinib Docetaxel	A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE)	Suspended	USA	0
NCT04524689	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701	Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)	Active, not recruiting	USA \| ISR \| HUN \| FRA \| ESP \| CZE \| BRA	1
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT04563338	Phase II	Atezolizumab Atezolizumab + Bevacizumab	An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)	Recruiting	CAN	0
NCT02892123	Phase I	Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25	Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers	Active, not recruiting	USA \| CAN	1
NCT06003075	Phase II	Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab	Induction Chemo-Nivo in Unresectable Stage III NSCLC	Terminated	USA	0
NCT03396497	Phase I	LYC-55716 + Pembrolizumab	Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer	Unknown status	USA	0
NCT02019979	Phase II	Metformin	Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO)	Terminated	USA	0
NCT04130516	Phase Ib/II	LNS8801 LNS8801 + Pembrolizumab	Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab	Recruiting	USA	0
NCT04262856	Phase II	AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab	Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)	Active, not recruiting	USA \| CAN \| AUS	4
NCT05502237	Phase III	AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab	Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)	Active, not recruiting	USA \| TUR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| ARG	9
NCT04925986	Phase II	Pembrolizumab + Sitravatinib	Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC	Terminated	USA	0
NCT04642469	Phase III	Durvalumab	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)	Completed	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	9
NCT05211895	Phase III	Durvalumab AB154 + Durvalumab	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)	Recruiting	USA \| TUR \| ROU \| POL \| NOR \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL	11
NCT03475953	Phase Ib/II	Avelumab + Regorafenib	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	Recruiting	FRA	0
NCT03293680	Phase II	Pembrolizumab	Pembrolizumab in Elderly Patients With Advanced Lung Cancer	Completed	ESP	0
NCT05259319	Phase I	Atezolizumab + Tiragolumab	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)	Recruiting	FRA	0
NCT04787042	Phase Ib/II	Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067	Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067	Active, not recruiting	USA	0
NCT04622007	Phase II	Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib	Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)	Active, not recruiting	USA \| AUS	1
NCT03580694	Phase I	Cemiplimab + REGN4659 Cemiplimab	Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA	0
NCT03003468	Phase Ib/II	Pembrolizumab + PGG beta-glucan	Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017	Completed	USA	0
NCT04260802	Phase Ib/II	OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001	A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers	Recruiting	CAN	0
NCT04903873	Phase Ib/II	EU101	A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors	Recruiting	USA	1

Gene Detail

Contact

Filtering

Sorting